» Articles » PMID: 3258520

Detection of the Terminal Complement Complex in Patient Plasma Following Acute Myocardial Infarction

Overview
Journal Atherosclerosis
Publisher Elsevier
Date 1988 Mar 1
PMID 3258520
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The mechanisms of inflammation responsible for the myocardial tissue damage seen after an acute myocardial infarction (AMI) have not been clearly identified. Recent lines of evidence, demonstrating depressed sera levels of individual complement components in patients after myocardial infarction, have suggested involvement of the complement (C) system in micro- and macrovascular injury subsequent to AMI. The present study assessed the role of complement as a mediator of myocardial inflammation by quantifying products of complement activation including, the terminal complement complex (TCC) the cytolytic component of the complement system, C1rC1s-C1 inhibitor complex and C3bBbP complex, formed following activation of the classical and alternative pathway, respectively, and anaphylatoxins C3a and C5a in 41 patients following AMI. Plasma TCC and C1rC1s-C1 inhibitor complex concentrations increased up to 32-fold (P less than 0.001) and 8-fold (P less than 0.001), respectively, while the C3bBbP complex, C3a des-Arg and C5a des-Arg each increased over 2-fold (P less than 0.001) 16 h after AMI, and were only minimally detectable during non-inflammatory myocardial conditions. Furthermore, TCC concentrations increased over 150% (P less than 0.001) one day after patients reinfarcted, subsequent to hospitalization for a primary AMI. These results demonstrate activation of complement after AMI and suggest that inflammatory mediators of the complement system may contribute to myocardial tissue damage during the infarction process.

Citing Articles

Serum complements and heart fatty acid binding protein in Bangladeshi patients with acute myocardial infarction.

Akhtar N, Taher A, Rahman R, Chowdhury A Heart Asia. 2016; 4(1):125-8.

PMID: 27326047 PMC: 4832623. DOI: 10.1136/heartasia-2012-010164.


Complement activation: an emerging player in the pathogenesis of cardiovascular disease.

Carter A Scientifica (Cairo). 2013; 2012:402783.

PMID: 24278688 PMC: 3820556. DOI: 10.6064/2012/402783.


Complement activation and prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.

Mellbin L, Bjerre M, Thiel S, Hansen T Diabetes Care. 2012; 35(4):911-7.

PMID: 22357179 PMC: 3308270. DOI: 10.2337/dc11-1642.


New insights of an old defense system: structure, function, and clinical relevance of the complement system.

Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M Mol Med. 2010; 17(3-4):317-29.

PMID: 21046060 PMC: 3060978. DOI: 10.2119/molmed.2010.00149.


Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1.

Hamad O, Nilsson P, Wouters D, Lambris J, Ekdahl K, Nilsson B J Immunol. 2010; 184(5):2686-92.

PMID: 20139276 PMC: 2953618. DOI: 10.4049/jimmunol.0902810.